Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
2
33%
Ph phase_3
1
17%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 3Large-scale testing
1(16.7%)
N/ANon-phased studies
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 31 (16.7%)
N/A2 (33.3%)

Trials by Status

completed583%
terminated117%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_1

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01312389
completedphase_1

A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects

NCT00000713
completedphase_1

A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC

NCT00000735
completedphase_3

The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

NCT00215800
completednot_applicable

A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection

NCT00001000
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01312389Phase 1

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Terminated
NCT00000713Phase 1

A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects

Completed
NCT00000735Phase 1

A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC

Completed
NCT00215800Phase 3

The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome

Completed
NCT00001000Not Applicable

A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection

Completed
NCT00002269Not Applicable

A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6